Synthetic CB2-selective cannabinoid

Plain-language summaryIntrigue 52 / 100

HU-308 is a synthetic cannabinoid built by the Mechoulam laboratory in Jerusalem to bind the CB2 receptor about 440 times more tightly than CB1. CB2 receptors live mostly on immune cells outside the brain, so a CB2-selective compound activates immune signaling without producing the psychoactive high that comes from CB1 engagement. It is used almost exclusively as a research probe to dissect what CB2 does in inflammation, bone metabolism, and tissue protection, and to validate CB2 as a drug target without confounding CB1 effects. Not a clinical compound; lives entirely in the lab. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

46/100

The canonical CB2-selective research probe; solid bench utility but aging mechanism and thin clinical translation

HU-308 earns its place in the library not because it’s exciting to read about in 2025, but because it’s genuinely hard to do rigorous CB2 pharmacology without it. Mechoulam’s group at Hebrew University synthesized it in the late 1990s, right when CB2’s immune-centric expression pattern was starting to attract serious attention. The pinene scaffold, the dimethoxyphenyl substitution, the greater-than-440-fold selectivity over CB1 – that selectivity profile is why it became the canonical probe. Before HU-308 and a handful of contemporaries, clean CB2 pharmacology was difficult to isolate from psychoactive CB1 noise. It solved a real experimental problem, and that problem is still real.

The mechanism story is fully mapped: Gi/o coupling, cAMP suppression, ERK activation in macrophages, microglia, B cells, T cells. CB2 sits at the intersection of peripheral immune modulation and pain signaling, so there’s real biology to interrogate. Anti-inflammatory effects in IBD models, neuropathic pain attenuation, hepatoprotective signal in ischemia-reperfusion – these aren’t trivial endpoints. Multiple labs have replicated the basic pharmacology across years and species. That cross-lab replication actually matters for a probe compound, and its one of HU-308’s strongest selling points.

What holds it back on the overall score is the translational picture. The CB2 agonist class has had a rough time moving from bench to bedside. Several CB2-selective programs in pain and inflammation have entered clinical trials and returned mediocre or null efficacy data. The biology appears real but translation has proven harder than preclinical data suggested. HU-308 itself isnt a development candidate at this point – its role is as a research tool, not a lead compound, and the overall field hasn’t validated the clinical hypothesis cleanly.

Honestly, the novelty picture is modest. This compound is over two decades old, the mechanism is fully characterized, and the receptor expression atlas is well-understood. If you’re scoring on frontier excitement it doesn’t compete with mitochondrial peptides or novel incretin scaffolds. What we think keeps it relevant is that CB2 biology keeps generating new questions – neuroinflammation, microglial activation states, peripheral sensitization in chronic pain – and HU-308 remains a clean way to ask those questions without psychoactive confounds contaminating your readout.

For a lab running a CB2-focused program, it’s essentially indispensable. For someone probing whether the CB2 axis is implicated in their disease model, it’s the correct tool. Outside of those use cases, theres limited reason to reach for it. The bench value score reflects the genuine indispensability within its niche; the overall score reflects that the niche is real but narrow, and the mechanism age and clinical translation struggles pull the compound well below frontier territory.

Novelty: 32
Mechanism promise: 40
In-category differentiation: 62
Evidence quality: 48
Translational signal: 32
Research bench value: 70

Rationale HU-308 scores well on bench value because it remains the go-to CB2 probe for clean pharmacology without CB1 confounds, but novelty is low for a 25-year-old compound with a fully mapped mechanism, and the CB2 agonist class has underdelivered in clinical translation, keeping evidence and translational scores modest.

Synthetic CB2-selective cannabinoid

A synthetic CB2-selective cannabinoid agonist; a research tool for CB2 pharmacology without psychoactive CB1 activity.

Abstract

HU-308 ([4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl]methanol; CAS 256934-39-1; molecular formula C27H42O4; molecular weight 430.62) is a synthetic CB2-selective cannabinoid agonist developed by Mechoulam and colleagues at Hebrew University. The compound is a pinene-scaffold cannabinoid with high CB2 affinity (Ki approximately 23 nM) and minimal CB1 binding (greater than 440-fold selectivity), eliminating the psychoactivity associated with CB1-mediated cannabinoid effects. CB2 is expressed predominantly in peripheral immune cells (macrophages, B cells, T cells, microglia in CNS); selective activation produces anti-inflammatory and analgesic effects without psychotropic side effects. Preclinical studies demonstrate efficacy in inflammatory bowel disease, neuropathic pain, hepatic ischemia, and atherosclerosis models. Plasma half-life is approximately 2 to 3 hours. Used as the canonical CB2-selective research probe in academic immunology and pain research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-327Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Synthetic CB2-selective cannabinoid

HU-308

Abstract

Read the full monograph